1. Lucendo AJ, Molina-Infante J, Arias Á, von Arnim U, Bredenoord AJ, Bussmann C, Amil Dias J, Bove M, González-Cervera J, Larsson H, Miehlke S, Papadopoulou A, RodríguezSánchez J, Ravelli A, Ronkainen J, Santander C, Schoepfer AM, Storr MA, Terreehorst I, Straumann A, Attwood SE. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017; 5(3): 335-358. https://doi.org/10.1177/2050640616689525 2. Ивашкин В.Т., Баранская Е.К., Кайбышева В.О., Трухманов А.С., Шептулин А.А. Клинические рекомендации по диагностике и лечению эозинофильного эзофагита. М., 2013. [Ivashkin V.T., Baranskaya E.K., Kaibysheva V.O., Trukhmanov A.S., Sheptulin A.A. Klinicheskie rekomendatsii po diagnostike i lecheniyu eozinofil'nogo ezofagita. M., 2013. (In Russ.)] 3. Кайбышева В.О., Михалева Л.М. Эозинофильный эзофагит, Издательство Медиа Сфера, 2021 4. Кайбышева В.О., Кашин С.В., Михалева Л.М., Видяева Н.С., Куваев Р.О., Галкова З.В., Ильчишина Т.А., Печникова В.В., Никонов Е.Л., Шаповальянц С.Г. Эозинофильный эзофагит: современный взгляд на проблему и собственные клинические наблюдения. Доказательная гастроэнтерология. 2019;8(1):58-83. https://doi.org/10.17116/dokgastro2019801158 5. Кайбышева В.О., Михалева Л.М., Никонов Е.Л., Шаповальянц С.Г. Эпидемиология, этиология и патогенез эозинофильного эзофагита. Новейшие данные. Доказательная гастроэнтерология. 2019;8(2):5072. Kaibysheva VO, Mikhaleva LM, Nikonov EL, Shapoval’yants SG. Epidemiology, etiology and pathogenesis of eosinophilic esophagitis. The latest data. Russian Journal of Evidence-Based Gastroenterology. 2019;8(2):5072. (In Russ., In Engl.). https://doi.org/10.17116/dokgastro2019802150 6. Arias A, Perez-Martinez I, Tenias JM, Lucendo AJ. Systematic review with meta- analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther 2016;43:3-15. https://doi.org/10.1111/apt.13441 7. van Rhijn BD, Verheij J, Smout AJ, Bredenoord AJ. Rapidly increasing incidence of eosinophilic esophagitis in a large cohort. Neurogastroenterol Motil 2013;25:47-5. https://doi.org/10.1111/nmo.12009 8. Warners M, de Rooij WE, Van Rhijn BD, Verheij J, Smout AJ, Bredenoord AJ. Large Increase in Incidence of Eosinophilc Esophagitis Over the Last 20 Years in the Netherlands: Results from a Nationwide Pathology Database. Gastroenterology 2017;152:862-863. https://doi.org/10.1016/S0016-5085(17)32964-5 9. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med 2004;351:940-1. 10. Dellon ES, Hirano I. Epidemiology and Natural History of Eosinophilic Esophagitis. Gastroenterology. 2018;154(2):319-332. https://doi.org/10.1053/j.gastro.2017.06.06 11. Prasad GA, Alexander JA, Schleck CD, Zinsmeister AR, Smyrk TC, Elias RM, Locke GR, Talley NJ. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2009;7:1055-61. https://doi.org/10.1016/j.cgh.2009.06.023 12. Syed AA, Andrews CN, Shaffer E, Urbanski SJ, Beck P, Storr M. The rising incidence of eosinophilic oesophagitis is associated with increasing biopsy rates: a population-based study. Aliment Pharmacol Ther 2012;36:950-8. https://doi.org/10.1111/apt.12053 13. Dellon ES, Erichsen R, Baron JA, Shaheen NJ, Vyberg M, Sorensen HT, Pedersen L. The increasing incidence and prevalence of eosinophilic oesophagitis outpaces changes in endoscopic and biopsy practice: national population-based estimates from Denmark. Aliment Pharmacol Ther 2015;41:662-70. https://doi.org/10.1111/apt.13129 14. Giriens B, Yan P, Safroneeva E, Zwahlen M, Reinhard A, Nydegger A, Vavricka S, Sempoux C, Straumann A, Schoepfer AM. Escalating incidence of eosinophilic esophagitis in Canton of Vaud, Switzerland, 1993-2013: a population-based study. Allergy 2015;70:1633-9. https://doi.org/10.1111/all.12733 15. Straumann A, Simon HU. Eosinophilic esophagitis: escalating epidemiology? J Allergy Clin Immunol 2005;115:418-9. https://doi.org/10.1016/j.jaci.2004.11.006 16. Dellon ES, Liacouras CA, Molina-Infante J et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology. 2018 Sep 6. pii: S0016-5085(18)34763-2. https://doi.org/10.1053/j.gastro.2018.07.009. 17. Straumann A, Katzka DA. Diagnosis and Treatment of Eosinophilic Esophagitis. Gastroenterology. 2018 Jan;154(2):346-359. https://doi.org/10.1053/j.gastro.2017.05.066 18. Lucendo AJ, Friginal-Ruiz AB, Rodriguez B. Boerhaave's syndrome as the primary manifestation of adult eosinophilic esophagitis. Two case reports and a review of the literature. Dis Esophagus 2011;24:E11-5. https://doi.org/10.1111/j.1442- 2050.2010.01167.x 19. Straumann A, Bussmann C, Zuber M, et al. Eosinophilic esophagitis: analysis of food impaction and perforation in 251 adolescent and adult patients. Clin Gastroenterol Hepatol 2008;6:598- 600. https://doi.org/10.1016/j.cgh.2008.02.003 20. Jackson WE, Mehendiratta V, Palazzo J, et al. Boerhaave's syndrome as an initial presentation of eosinophilic esophagitis: a case series. Ann Gastroenterol 2013;26:166- 169. 21. Dhar A, Haboubi HN, Attwood SE, Auth MKH, Dunn JM, Sweis R, Morris D, Epstein J, Novelli MR, Hunter H, Cordell A, Hall S, Hayat JO, Kapur K, Moore AR, Read C, Sami SS, Turner PJ, Trudgill NJ. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut. 2022 Aug;71(8):1459-1487. doi: 10.1136/gutjnl-2022-327326. Epub 2022 May 23. PMID: 35606089; PMCID: PMC9279848. 22. Ивашкин В.Т., Баранская Е.К., Кайбышева В.О., Иванова Е.В., Федоров Е.Д. Эозинофильный эзофагит: обзор литературы и описание собственного наблюдени. РЖГГК;2012: 1. 71–81. [Ivashkin V.T., Baranskaya E.K., Kaibysheva V.O., Ivanova E.V., Fedorov E.D. Eozinofil'nyi ezofagit: obzor literatury i opisanie sobstvennogo nablyudeniya // RZhGGK. 2012: 1. 71–81. (In Russ.)] 23. Dellon ES, Gibbs WB, Fritchie KJ, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2009;7:1305–1313. 24. Remedios M, Campbell C, Jones DM, et al. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc 2006;63:3–12. 25. Croese J, Fairley SK, Masson JW, et al. Clinical and endoscopic features of eosinophilic esophagitis in adults. Gastrointest Endosc 2003;58:516–522. 26. Kahn J, Bussmann C, Beglinger C, et al. Exercise-induced chest pain: an atypical manifestation of eosinophilic esophagitis. Am J Med 2015;128:196–199. https://doi.org/10.1016/j.amjmed.2014.08.007 27. Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006;64:313–319. 28. Shah A, Kagalwalla AF, Gonsalves N, et al. Histopathologic variability in children with eosinophilic esophagitis. Am J Gastroenterol 2009;104:716–721. 29. Peery AF, Cao H, Dominik R, et al. Variable reliability of endoscopic findings with whitelight and narrow-band imaging for patients with suspected eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011;9:475–480. https://doi.org/10.1016/j.cgh.2011.02.026 30. Dellon ES, Speck O, Woodward K. The patchy nature of esophageal eosinophilia in eosinophilic esophagitis: Insights from pathology samples from a clinical trial. Gastroenterology 2012;142(Suppl):Su-1129. https://doi.org/10.1016/S0016- 5085(12)61626-6 31. DeBrosse CW, Collins MH, Buckmeier Butz BK, et al. Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982-1999. J Allergy Clin Immunol 2010;126:112–9. 32. Kim HP, Vance RB, Shaheen NJ, et al. The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:988–996. https://doi.org/10.1016/j.cgh.2012.04.019 33. Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut 2013;62:489-95. https://doi.org/10.1136/gutjnl-2011-301817 34. Dellon ES, Gibbs WB, Fritchie KJ, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2009;7:1305-13; https://doi.org/10.1016/j.cgh.2009.08.030 35. Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology 2013;145:1230–2. 36. Lipka S, Kumar A, Richter JE. Impact of diagnostic delay and other risk factors on eosinophilic esophagitis phenotype and esophageal diameter. J Clin Gastroenterol 2016;50:134–40. 37. Warners MJ, Oude Nijhuis RAB, de Wijkerslooth LRH, et al. The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort. Am J Gastroenterol 2018;113:836–44. 38. Peterson KA, Byrne KR, Vinson LA, et al. Elemental diet induces histologic response in adult eosinophilic esophagitis. Am J Gastroenterol 2013;108:759- 766. https://doi.org/10.1038/ajg.2012.468 39. Arias A, Gonzalez-Cervera J, Tenias JM, et al. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology 2014;146:1639–1648. https://doi.org/10.1053/j.gastro.2014.02.006 40. Spergel JM, Beausoleil JL, Mascarenhas M, et al. The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol 2002;109:363–368. 41. Spergel JM, Brown-Whitehorn TF, Cianferoni A, et al. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. J Allergy Clin Immunol 2012;130:461–467. https://doi.org/10.1016/j.jaci.2012.05.021 42. Kagalwalla AF, Shah A, Ritz S, et al. Cow’s milk protein-induced eosinophilic esophagitis in a child with gluten-sensitive enteropathy. J Pediatr Gastroenterol Nutr 2007;44:386– 388. https://doi.org/10.1097/01.mpg.0000243430.32087.5c 43. Wolf WA, Jerath MR, Sperry SLW, et al. Dietary elimination therapy is an effective option for adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2014;12:1272–1279. https://doi.org/10.1016/j.cgh.2013.12.034 44. Molina-Infante J, Martin-Noguerol E, Alvarado-Arenas M, et al. Selective elimination diet based on skin testing has suboptimal efficacy for adult eosinophilic esophagitis. J Allergy Clin Immunol 2012;130:1200–1202. https://doi.org/10.1016/j.jaci.2012.06.027 45. Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006;4:1097–1102. 46. Henderson CJ, Abonia JP, King EC, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2012;129:1570– 1578. https://doi.org/10.1016/j.jaci.2012.03.023 47. Kagalwalla AF, Shah A, Li BUK, et al. Identification of specific foods responsible for inflammation in children with eosinophilic esophagitis successfully treated with empiric elimination diet. J Pediatr Gastroenterol Nutr 2011;53:145–149. https://doi.org/10.1097/MPG.0b013e31821cf503 48. Molina-Infante J, Arias A, Barrio J, et al. Four-food group elimination diet for adult eosinophilic esophagitis: A prospective multicenter study. J Allergy Clin Immunol 2014;134:1093–1099. https://doi.org/10.1016/j.jaci.2014.07.023 49. Philpott H, Nandurkar S, Royce SG, et al. Allergy tests do not predict food triggers in adult patients with eosinophilic oesophagitis. A comprehensive prospective study using five modalities. Aliment Pharmacol Ther 2016 ;44:223– 233. https://doi.org/10.1111/apt.13676 50. Kagalwalla AF, Amsden K, Shah A, et al. Cow’s milk elimination: a novel dietary approach to treat eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2012;55:711–716. https://doi.org/10.1097/MPG.0b013e318268da40 51. Kruszewski PG, Russo JM, Franciosi JP, et al. Prospective, comparative effectiveness trial of cow’s milk elimination and swallowed fluticasone for pediatric eosinophilic esophagitis. Dis Esophagus 2016;29:377–384. https://doi.org/10.1111/dote.12339 52. Molina-Infante J, Arias Á, Alcedo J, Garcia-Romero R, Casabona-Frances S, Prieto-Garcia A, Modolell I, Gonzalez-Cordero PL, Perez-Martinez I, Martin-Lorente JL, GuarnerArgente C, Masiques ML, Vila-Miravet V, Garcia-Puig R, Savarino E, Sanchez-Vegazo CT, Santander C, Lucendo AJ. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study. J Allergy Clin Immunol. 2018;141(4):1365- 1372. https://doi.org/10.1016/j.jaci.2017.08.038 53. Gonsalves N, Yang G-Y, Doerfler B, et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 2012;142:1451–1455. https://doi.org/10.1053/j.gastro.2012.03.001 54. Lucendo AJ, Arias A, Gonzalez-Cervera J, et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol 2013;131:797– 804. https://doi.org/10.1016/j.jaci.2012.12.664 55. Moawad FJ, Veerappan GR, Dias JA, et al. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol 2013;108:366–372. https://doi.org/10.1038/ajg.2012.443 56. Peterson KA, Thomas KL, Hilden K, et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 2010;55:1313–1319. https://doi.org/10.1007/s10620-009-0859-4 57. Cheng E, Zhang X, Huo X, Yu C, Zhang Q, Wang DH, Spechler SJ, Souza RF. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2013 Jun;62(6):824-32. https://doi.org/10.1136/gutjnl-2012-302250. 58. Ngo P, Furuta GT, Antonioli DA, et al. Eosinophils in the esophagus--peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol 2006;101:1666–1670. 59. Dranove JE, Horn DS, Davis MA, et al. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr 2009;154:96– 100. https://doi.org/10.1016/j.jpeds.2008.07.042 60. Molina-Infante J, Ferrando-Lamana L, Ripoll C, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol 2011; 9: 110–117. https://doi.org/10.1016/j.cgh.2010.09.019 61. Gutierrez-Junquera C, Fernandez-Fernandez S, Cilleruelo ML, et al. High revalence of response to proton-pump inhibitor treatment in children with esophageal eosinophilia. J Pediatr Gastroenterol Nutr 2016;62:704–710. https://doi.org/10.1097/MPG.0000000000001019 62. Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:13–22. https://doi.org/10.1016/j.cgh.2015.07.041 63. Cheng E, Zhang X, Wilson KS, Wang DH, Park JY, Huo X, Yu C, Zhang Q, Spechler SJ, Souza RF. JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE. PLoS One. 2016 Jun 16;11(6):e0157376. https://doi.org/10.1371/journal.pone.0157376. 64. Dellon ES, Liacouras CA. Advances in clinical management of eosinophilic esophagitis. Gastroenterology 2014;147:1238–1254. https://doi.org/10.1053/j.gastro.2014.07.055 65. Molina-Infante J, Rodriguez-Sanchez J, Martinek J, et al. Long-term loss of response in proton pump inhibitor-responsive esophageal eosinophilia is uncommon and influenced by CYP2C19 genotype and rhinoconjunctivitis. Am J Gastroenterol 2015;110:1567–1575. https://doi.org/10.1038/ajg.2015.314 66. Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008;6:165–173. 67. Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012;10:742–749. https://doi.org/10.1016/j.cgh.2012.03.018 68. Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2015;13:66– 76. https://doi.org/10.1016/j.cgh.2014.05.021 69. Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010;139:418–429. https://doi.org/10.1053/j.gastro.2010.05.001 70. Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebocontrolled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006;131:1381–1391. 71. Dellon ES, Sheikh A, Speck O, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology 2012;143:321– 324. https://doi.org/10.1053/j.gastro.2012.04.049 72. Butz BK, Wen T, Gleich GJ, et al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology 2014;147:324–333. https://doi.org/10.1053/j.gastro.2014.04.019 73. Miehlke S, Hruz P, Vieth M, et al. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut 2016;65:390–399. https://doi.org/10.1136/gutjnl-2014-308815 74. Tan N Di, Xiao YL, Chen MH. Steroids therapy for eosinophilic esophagitis: Systematic review and meta-analysis. J Dig Dis 2015;16:431–442. https://doi.org/10.1111/1751- 2980.12265 75. Sawas T, Dhalla S, Sayyar M, et al. Systematic review with meta-analysis: pharmacological interventions for eosinophilic oesophagitis. Aliment Pharmacol Ther 2015;41:797–806. https://doi.org/10.1111/apt.13147 76. Murali AR, Gupta A, Attar BM, et al. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo controlled randomized clinical trials. J Gastroenterol Hepatol 2015; 31:1111-1119. https://doi.org/10.1111/jgh.13281 77. Chuang M-YA, Chinnaratha MA, Hancock DG, et al. Topical steroid therapy for the treatment of eosinophilic esophagitis (EoE): a systematic review and meta- analysis. Clin Transl Gastroenterol 2015;6:e82. https://doi.org/10.1038/ctg.2015.9 78. Straumann A, Conus S, Degen L, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011;9:400–409. https://doi.org/10.1016/j.cgh.2011.01.017 79. Philla KQ, Min SB, Hefner JN, et al. Swallowed glucocorticoid therapy for eosinophilic esophagitis in children does not suppress adrenal function. J Pediatr Endocrinol Metab 2015;28:1101–1106. https://doi.org/10.1515/jpem-2014-0260 80. Golekoh MC, Hornung LN, Mukkada VA, et al. Adrenal insufficiency after chronic swallowed glucocorticoid therapy for eosinophilic esophagitis. J Pediatr 2016;170:240– 245. https://doi.org/10.1016/j.jpeds.2015.11.026 81. Harel S, Hursh BE, Chan ES, et al. Adrenal suppression in children treated with oral viscous budesonide for eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2015;61:190–193. https://doi.org/10.1097/MPG.0000000000000848 82. Moawad FJ, Cheatham JG, DeZee KJ. Meta-analysis: the safety and efficacy of dilation in eosinophilic oesophagitis. Aliment Pharmacol Ther 2013;38:713–720. https://doi.org/10.1111/apt.12438 83. Netzer P, Gschossmann JM, Straumann A, et al. Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol 2007;19:865–869. 84. Abonia JP, Blanchard C, Butz BB, et al. Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol 2010;126:140–149. https://doi.org/10.1016/j.jaci.2010.04.009 85. Arias A, Lucendo AJ, Martinez-Fernandez P, et al. Dietary treatment modulates mast cell phenotype, density, and activity in adult eosinophilic oesophagitis. Clin Exp Allergy 2016;46:78–91. https://doi.org/10.1111/cea.12504 86. Liacouras CA, Spergel JM, Ruchelli E, et al. Eosinophilic esophagitis: A 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005;3:1198–1206. 87. Attwood SEA, Lewis CJ, Bronder CS, et al. Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut 2003;52:181–185. 88. Stumphy J, Al-Zubeidi D, Guerin L, Mitros F, Rahhal R. Observations on use of montelukast in pediatric eosinophilic esophagitis: insights for the future. Dis Esophagus. Australia; 2011;24(4):229–34. https://doi.org/10.1111/j.1442-2050.2010.01134.x 89. Alexander JA, Ravi K, Enders FT, Geno DM, Kryzer LA, Mara KC, Smyrk TC, Katzka DA. Montelukast Does not Maintain Symptom Remission After Topical Steroid Therapy for Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2017;15(2):214-221.e2. https://doi.org/10.1016/j.cgh.2016.09.013 90. Lucendo AJ, De Rezende LC, Jimenez-Contreras S, et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci 2011;56:3551–3558. https://doi.org/10.1007/s10620-011-1775-y 91. Straumann A, Bauer M, Fischer B, Blaser K, Simon H-U. Idiopathic eosinophilic esophagitis is associated with a Th2-type allergic inflammatory response. J Allergy Clin Immunol. 2001; 108(6): 954–61 92. O’Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol. 2001; 108(4):503–8. 93. Mishra A, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology. 2003; 125(5):1419–27. 94. Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo- controlled, double-blind trial. Gut 2010;59:21–30. https://doi.org/10.1136/gut.2009.178558 95. Assa’ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011;141:1593–1604. https://doi.org/10.1053/j.gastro.2011.07.044 96. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012;129:456–463. https://doi.org/10.1016/j.jaci.2011.11.044 97. Zuo L, Fulkerson PC, Finkelman FD, Mingler M, Fischetti CA, et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13Rα2- inhibited pathway. J Immunol. 2010; 185(1):660–69. https://doi.org/10.4049/jimmunol.1000471 98. Doran E, Cai F, Holweg CTJ, Wong K, Brumm J, Arron JR. Interleukin-13 in Asthma and Other Eosinophilic Disorders. Front Med (Lausanne). 2017 Sep 19;4:139. https://doi.org/110.3389/fmed.2017.00139 99. Davis BP, Stucke EM, Khorki ME, et al. Eosinophilic esophagitis-linked calpain 14 is an IL-13- induced protease that mediates esophageal epithelial barrier impairment. JCI Insight 2016;1:86355. https://doi.org/10.1172/jci.insight.86355 100. Rothenberg ME, Wen T, Greenberg A, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2015;135:500-7. https://doi.org/10.1016/j.jaci.2014.07.049. 101. Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy. 2005; 35(8):1096–103. 102. Spergel BL, Ruffner MA, Godwin BC et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022 May;128(5):589-593. doi: 10.1016/j.anai.2022.01.019. Epub 2022 Jan 25. PMID: 3508581 103. Laserna-Mendieta EJ, Casabona S, Guagnozzi D, et al. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoEconnect registry. Aliment Pharmacol Ther 2020;52:798–807. 104. Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebocontrolled trial. Gastroenterology 2019;157:74–86. 105. Straumann A, Lucendo AJ, Miehlke S, et al. Budesonide Orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology 2020;159:1672–85.